Best Cytokine Signalling Forum Podcasts (2025)

1
Discussing RA: Real-world evaluation of JAKi efficacy, persistence, and cardiovascular safety in RA 9:45

Play Pause

3h ago9:45

9:45

Discussing RA: Real-world evaluation of JAKi efficacy, persistence, and cardiovascular safety in RA by The Immune-Mediated Inflammatory Disease ForumBy The Immune-Mediated Inflammatory Disease Forum

1
Author Interview: Professor Filip Rob, 2025 25:07

12h ago25:07

25:07

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Filip Rob, the Department of head of the Dermatovenereology at the Second Faculty of Medicine, Charles University, University Hospital Bulovka, Prague, Czech Republic, as they discuss his recent paper ‘Efficacy, safety, and drug survival during the first year of biolo…

1
Webinar Highlights: Advancing Patient Care Through an Interdisciplinary Approach to IMIDs: Part 2 17:02

5h ago17:02

17:02

Webinar highlights! Join Professor Iain McInnes and Drs Grace Wright and Melinda Gooderham as they discuss advancing patient care through an interdisciplinary approach to IMIDs. This webinar provides information on bridging care pathways, advancing IMID treatment, and case studies of interdisciplinary care.…

1
Discussing axSpA: Adalimumab dosing and uveitis recurrence in patients with ankylosing spondylitis 14:37

10h ago14:37

14:37

Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the Association between adalimumab dosing interval and uveitis recurrence in patients with ankylosing spondylitis.By The Immune-Mediated Inflammatory Disease Forum

1
Discussing RA: Long-term management of elderly patients with RA treated with tocilizumab 5:15

5h ago5:15

5:15

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, Iain will review a paper by B Fautrel, in which authors compare patient characteristics and long-term management with tocilizumab in RA patients over and under 75 years of age, and tolerance of RA treatments.…

1
ACR 2025 Review Podcast 40:15

10d ago40:15

40:15

Join Doctor Sofia Ramiro and Professors Janet Pope and Atul Deodhar, as they review and discuss key data from ACR 2025 across RA, PsA, and axSpA, focusing on implications for clinical practice.By The Immune-Mediated Inflammatory Disease Forum

1
ACR Daily Highlights Day 4 1:48

28d ago1:48

1:48

Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 4 of ACR 2025 (Wednesdsy, 29th of October)By The Immune-Mediated Inflammatory Disease Forum

1
ACR Daily Highlights: Day 3 3:49

26d ago3:49

3:49

Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 3 of ACR 2025 (Tuesday 28th of October)By The Immune-Mediated Inflammatory Disease Forum

1
Pathways Modulating IMIDs: Webinar Highlights Podcast 24:49

27d ago24:49

24:49

Professors Janet Pope and John Isaacs discuss all the highlights from the 'Pathways Modulating IMIDs' webinar.By The Immune-Mediated Inflammatory Disease Forum

1
ACR Daily Highlights: Day 2 4:03

27d ago4:03

4:03

Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 2 of ACR 2025 (Monday, 27th of October)By The Immune-Mediated Inflammatory Disease Forum

1
ACR Daily Highlights: Day 1 3:49

1M ago3:49

3:49

Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 1 of ACR 2025 (Sunday, 26th of October)By The Immune-Mediated Inflammatory Disease Forum

1
ACR 2025 Preview Podcast 22:47

1M ago22:47

22:47

Join Professors Peter Nash, Janet Pope and Atul Deodhar as they preview what they are most looking forward to this ACR, introducing some of the top chosen abstracts and posters in RA, AxSpA and PsA so that you can better plan your time at what will be a busy and exciting congress. #ACR2025By The Immune-Mediated Inflammatory Disease Forum

1
Discussing PsA: Comparative effectiveness of biologic and targeted therapies in PsA: Insights from PARWCH and KEEPsAKE studies 18:31

2M ago18:31

18:31

Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the effectiveness and safety of upadacitinib with secukinumab and adalimumab’ and ‘the efficacy of long-term treatment with risankizumab across the updated GRAPPA domains and key related conditions of PsA…

1
Author Interview: Doctor David Kellner, September 2025 22:44

2M ago22:44

22:44

Join Professor Peter Nash from the Griffith University in Brisbane, and Doctor David Kellner, an IGNITE-MSCR Fellow of the Division of Rheumatology, from UCLA Medical Centre, LA, USA, as they discuss his recent review ‘Effect of glucagon-like peptide 1 receptor agonists on patients with rheumatoid arthritis’.…

1
Discussing RA: Safety and vaccine immunogenicity of upadacitinib across immune-mediated diseases 8:44

2M ago8:44

8:44

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he highlights two papers: risk of MACE, VTE, and malignancies in patients with RA or UC treated with filgotinib and frequency of reporting of MACE, MI, and stroke between JAKis and anti-TNFα.…

1
Discussing axSpA: Comparative real-world effectiveness of biologic and targeted therapies in axSpA 20:52

2M ago20:52

20:52

Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the effectiveness of ixekizumab in real-world patients with axSpA and PsA, and the real‑world comparison of clinical effectiveness of UPA, TNF inhibitors or IL‑17 inhibitors in patients with axSpA af…

1
Discussing RA: Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis 7:41

3M ago7:41

7:41

Join Professor Iain McInnes as he discusses the top publications in the world of RA. This month’s discussion covered the ‘Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis’. Read the full paper summary online at www.imidforum.com.…

1
Author Interview: Doctor Rodrigo Garcia‑Salinas, August 2025 28:57

3M ago28:57

28:57

Join Professor Peter Nash from Griffith University in Brisbane, and Dr Rodrigo Garcia‑Salinas from Hospital Italiano de La Plata in Argentina, as they discuss Dr Garcia-Salinas’ recent publication ‘Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns’.…

1
Author Interview: Doctor Martin Schaefer and Professor Anja Strangfeld, July 2025 45:23

3M ago45:23

45:23

Join Professor Peter Nash from the Griffith University in Brisbane, and authors Dr Martin Schaefer from the German Rheumatology Research Center in Berlin, Germany and Professor Anja Strangfeld, the head of epidemiology at the German Rheumatology Research Centre. In this episode they discuss a recent study from the German RABBIT registry, investigat…

1
Discussing PsA: Post hoc analyses on secukinumab and deucravacitinib from Phase 2 and 3 trials 17:45

4M ago17:45

17:45

Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the influence of csDMARDs use on efficacy and safety of deucravacitinib in pateints with PsA’ and ‘the incidence rate of uveitis in patients with axSpA and PsA treated with secukinumab’.…

1
Discussing RA: Comparative outcomes of JAK inhibition and TNF blockade vs dual JAK–ROCK targeting 13:24

4M ago13:24

13:24

Join Professor Iain McInnes as he discusses the top publications in the world of RA. This month, the conversation covered the ‘dual JAK and ROCK inhibition with CPL’116 in patients with RA with inadequate response to MTX’ and ‘the benefit–risk analysis of UPA versus adalimumab in patients with RA and higher or lower risk of cardiovascular disease’…

1
Discussing axSpA: Secukinumab treatment outcomes on sustained remission and skeletal health in axSpA 16:44

5M ago16:44

16:44

Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered treatment outcomes in European real-world patients with axSpA and PsA, treated with secukinumab and the effects of secukinumab on skeletal microarchitecture and vertebral fractures in patients with a…

1
Difficult-to-treat disease in Rheumatology Podcast Professors Iain McInnes and Peter Nash 41:27

5M ago41:27

41:27

Join Professor Iain McInnes from the University of Glasgow, and Professor Peter Nash from the Griffith University in Brisbane, as they discuss the concept of difficult-to-treat disease in rheumatology.By The Immune-Mediated Inflammatory Disease Forum

1
EULAR 2025 Review Podcast 1:05:19

5M ago1:05:19

1:05:19

Join Professors Xenofon Baraliakos, Laura Coates, and Johannes Bijlsma as they review their highlights of the recent EULAR 2025 congress, and watch them discuss the key abstracts and information.By The Immune-Mediated Inflammatory Disease Forum

1
Discussing RA: Impact of TOF on BMI, UPA monotherapy in MTX-IRs, and JAKis vs TNFis treatment 15:20

5M ago15:20

15:20

Join Professor Iain McInnes and Professor Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA. In this episode, they discuss three papers: the impact of TOF treatment on weight and BMI in RA patients, to that of alternate treatment options for RA patients with prior MTX-i…

1
EULAR 2025 Highlights: Day 4 3:25

6M ago3:25

3:25

Join Professor Xenofon Baraliakos as he summarises his top abstracts, posters, and presentations from Day 4 of EULAR 2025 (Saturday, June 14).By The Immune-Mediated Inflammatory Disease Forum

1
EULAR 2025 Highlights: Day 3 2:36

6M ago2:36

2:36

Join Professor Xenofon Baraliakos as he summarises his top abstracts, posters, and presentations from Day 3 of EULAR 2025 (Friday, June 13).By The Immune-Mediated Inflammatory Disease Forum

1
Discussing PsA: Real-world data on biologic switching and the development of EMMs 23:11

6M ago23:11

23:11

Join Professors Philip Mease and Laura Coates and as they discuss the top publications in the world of PsA. This month, the conversation covered a discussion on biologic switching for the treatment of PsA using real-world data as well as the development of extramusculoskeletal manifestations in PsA and axSpA patients treated with upadacitinib.…

1
EULAR 2025 Highlights: Day 2 4:39

6M ago4:39

4:39

Join Professor Xenofon Baraliakos as he summarises his top abstracts, posters, and presentations from Day 2 of EULAR 2025 (Thursday, June 12).By The Immune-Mediated Inflammatory Disease Forum

1
EULAR 2025 Highlights: Day 1 4:03

6M ago4:03

4:03

Join Professor Xenofon Baraliakos as he summarises his top abstracts, posters, and presentations from Day 1 of EULAR 2025 (Wednesday, June 11).By The Immune-Mediated Inflammatory Disease Forum

1
EULAR 2025 Preview Podcast 25:23

6M ago25:23

25:23

Join Professors Xenofon Baraliakos, Laura Coates, and Johannes Bijlsma as they guide you through what they are most looking forward to in RA, PsA, and axSpA at EULAR 2025, so that you can better plan your time at what will be a busy and exciting congress.By The Immune-Mediated Inflammatory Disease Forum

1
Discussing RA: MACE in RA, data from the "JAK-pot" study, and combination therapy in MTX-IR RA 10:25

6M ago10:25

10:25

Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest updates in RA. In this episode, he discusses two papers: risk of MACE in patients with RA treated with JAKis compared to bDMARDs from the “JAK-pot” study, and the efficacy and safety of zimlovisertib, ritlecitinib and …

1
Podcast: AuToDeCRA, June 2025 30:26

6M ago30:26

30:26

Join Professor Ian McInnes from the University of Glasgow, and Professors John Isaacs and Andrew Cope, as they discuss the latest AuToDeCRA study and what this means for rheumatology.By The Immune-Mediated Inflammatory Disease Forum

1
Webinar Highlights Podcast: Advancing Patient Care Through an Interdisciplinary Approach to IMIDs 23:13

6M ago23:13

23:13

Professor Iain McInnes and Drs Grace Wright and Melinda Gooderham discuss all the highlights from 'Advancing patient care through an interdisciplinary approach to IMIDs: Part 2'.By The Immune-Mediated Inflammatory Disease Forum

1
Author Interview: Dr Saqr Alsakarneh, May 2025 26:08

6M ago26:08

26:08

Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Saqr Alsakarneh, Internal Medicine Resident at University of Missouri–Kansas City in the US, as they discuss ‘Risk of De Novo Inflammatory Bowel Disease in Patients with Psoriasis and Psoriatic Arthritis Treated with IL-17A Inhibitors: A Population-Based Study’.…

1
Discussing axSpA: JAKi cycling and long-term safety of bimekizumab in patients with axSpA or PsA 32:17

7M ago32:17

32:17

Join Dr Sofia Ramiro and cohosts Professors Atul Deodhar, Hideto Kameda, and Xenofon Baraliakos for the latest episode of the discussing axSpA podcast on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in axSpA.In this episode, our faculty discusses two papers: the first assesses switching to secukinumab or cyc…

1
Discussing RA: MACE, VTE, and malignancy in filgotinib RA and UC patients, and MACE related to JAKis 8:31

7M ago8:31

8:31

Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest updates in RA. In this episode, he discusses two papers: risk of MACE, VTE, and malignancies in patients with RA or UC treated with filgotinib and frequency of reporting of MACE, MI, and stroke between JAKis and anti-T…

1
Highlights Podcast: IL-17 Inhibition: Controlling inflammation and disease progression in SpA 32:21

7M ago32:21

32:21

Highlights Podcast: IL-17 Inhibition: Controlling inflammation and disease progression in SpA by The Immune-Mediated Inflammatory Disease ForumBy The Immune-Mediated Inflammatory Disease Forum

1
Discussing PsA: JAKi Comparative safety & Burden and determinants of multi‑b/tsDMARD failure in PsA 29:23

8M ago29:23

29:23

Join Professors Laura Coates and Philip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered a discussion on the comparative safety of JAK inhibitors versus TNF or IL-17 inhibitors for cardiovascular disease and cancer in psoriatic arthritis and axial spondyloarthritis. They also give insights into th…

1
Discussing RA: Pain reduction & choosing second-line DMARDs after unresponsive first-line DMARDs 21:40

8M ago21:40

21:40

Join Professors Iain McInnes and Peter Nash for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA. In this episode, they discuss two papers: effectiveness of JAKi compared with bDMARDs on pain reduction and effective second‑line b/tsDMARD for patients with rheumatoid arthritis unrespon…

1
Author Interview: Professor Phillip Helliwell, March 2025 22:30

8M ago22:30

22:30

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Phillip Helliwell, Professor of rheumatology at The University of Leeds in the UK, as they discuss ‘Tight Control and Radiological Progression: The Radiographic Outcomes of the TICOPA Study’By The Immune-Mediated Inflammatory Disease Forum

1
Author Interview: Professor Phillip Helliwell, 2025 26:36

9M ago26:36

26:36

Author Interview: Professor Phillip Helliwell, 2025 by The Immune-Mediated Inflammatory Disease ForumBy The Immune-Mediated Inflammatory Disease Forum

1
Discussing PsA: Bimekizumab improves patient-reported outcomes and work productivity 32:04

9M ago32:04

32:04

Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered a discussion on the longer-term impact of bimekizumab on patient-reported outcomes, health-related QoL, and work productivity in patients with active PsA who were bDMARD-naïve or had an inadequate…

1
Discussing RA: Baricitinib dose reduction and switching to bDMARDs vs JAKis 11:17

9M ago11:17

11:17

Join Professors Iain McInnes, Hans Bijlsma, and Peter Nash for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA. In this episode, they discuss two papers: baricitinib dose reduction in patients with RA achieving sustained disease control and switching to bDMARDs vs cycling among JAKis…

1
Discussing axSpA: Long-term safety and efficacy of Bimekizumab results from BE-AGILE & BE-MOBILE 1/2 25:05

9M ago25:05

25:05

Join Dr Sofia Ramiro and cohosts Professors Atul Deodhar, Hideto Kameda, and Xenofon Baraliakos for the latest episode of the discussing axSpA podcast on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in axSpA.In this episode, our faculty discusses two papers both focusing on the long-term safety and efficacy …

1
Author Interview: Professor Denis McGonagle, 2025 36:01

10M ago36:01

36:01

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Denis McGonagle, Professor of investigative rheumatology at the NIHR funded Academic Unit for the Musculoskeletal Diseases and Leeds Teaching Hospitals NHS Trust in the UK, as they discuss his recent review ‘Subclinical psoriatic arthritis and disease interception—whe…

1
Discussing RA: Insights into sustained DMARD-free remission and barriers to CAR T-cell therapy 11:18

10M ago11:18

11:18

Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest updates in RA. In this episode, Professor McInnes discusses two papers: subgroups of patients with early RA with or without bDMARD who reached sustained DMARD-free remission and barriers to the widespread adoption of C…

1
Discussing AxSpA Podcast: Efficacy and Safety of Upadacitinib 18:42

11M ago18:42

18:42

Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar, and Xenfon Baraliakos to discuss a recent study on the efficacy and safety of upadacitinib in patient with ankylosing spondylitis.…

1
Discussing RA: Insights into Filgotinib and Tofacitinib in RA 24:13

11M ago24:13

24:13

Join Professor Iain McInnes and Professor Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA. In this episode, they discuss two papers which discuss the efficacy and safety of filgotinib, and lymphocyte count and infection risk associated with tofacitinib in rheumatoid a…

1
ACR 2024 Review Podcast 50:04

12M ago50:04

50:04

ACR 2024 Review Podcast by The Immune-Mediated Inflammatory Disease ForumBy The Immune-Mediated Inflammatory Disease Forum